SCHEMBL3603220

SCHEMBL3603220

Cc1nc(CO)ccc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 3/20 0.56
GABRD O14764 3/20 0.56
GABRA1 P14867 3/20 0.56
GABRB1 P18505 3/20 0.56
GABRG2 P18507 3/20 0.56
GABRB3 P28472 3/20 0.56
GABRA5 P31644 3/20 0.56
GABRA3 P34903 3/20 0.56
GABRA2 P47869 3/20 0.56
GABRB2 P47870 3/20 0.56
GABRA4 P48169 3/20 0.56
GABRE P78334 3/20 0.56
GABRA6 Q16445 3/20 0.56
GABRG1 Q8N1C3 3/20 0.56
GABRG3 Q99928 3/20 0.56
GABRQ Q9UN88 3/20 0.56
ALDH1A1 P00352 4/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
RAB9A P51151 2/20 0.49
RXFP1 Q9HBX9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1997423 0.85 SMN1; SMN2 (0.57) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4453924 0.83 GABRP (0.59) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL480125 0.83 GABRP (0.55) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL3653761 0.81 GABRP (0.53) GABRPGABRDGABRA1GABRB1GABRG2
Hydrochloric Acid SCHEMBL1169512 0.81 GABRP (0.58) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL27587609 0.79 GABRP (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL18973349 0.79 KDM4E (0.53) ALDH1A1RAB9AKDM4EHPGDCYP1A2
SCHEMBL13462372 0.78 SMN1; SMN2 (0.46) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL17632406 0.78 GABRP (0.49) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL12837796 0.77 TDP1 (0.62) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119613392-A Beta amyloid protein probe and preparation method and application thereof 四川大学华西医院 2025-03-14 CN disclosed
EP-2137162-B1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2018-08-01 EP disclosed
CN-106854207-A Dai piperazine analog derivative, its preparation method, pharmaceutical composition and purposes 上海赛默罗生物科技有限公司 2017-06-16 CN disclosed
US-8536168-B2 Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway NOVARTIS AG (CH) 2013-09-17 US disclosed
US-20100069368-A1 Organic Compounds and Their Uses NOVARTIS AG (CH) 2010-03-18 US disclosed
EP-2137162-A1 ORGANIC COMPOUNDS AND THEIR USES Novartis Ag (CH) 2009-12-30 EP disclosed
WO-2008110611-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069368-A1 Organic Compounds and Their Uses SHH, GLI1, VHL GABRP 4324/4885GABRD 4083/4885GABRA1 3849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.